Dr. Andrew Gianoukakis, MD – UCLA Faculty | oneGRAVESvoice

welcome to oneGRAVESvoice

- a positively charged Graves' disease and thyroid eye disease community.
  • join today!
Healthcare Professionals

Andrew G. Gianoukakis, MD

Healthcare Professional
David Geffen School of Medicine
University of California Los Angeles
10833 Le Conte Ave
Los Angeles, California, United States

Andrew G. Gianoukakis is a Professor of Medicine at the David Geffen School of Medicine at University of California Los Angeles (UCLA) and an expert in Thyroid Disorders with particular expertise in Advanced Thyroid Cancer and Graves ’ disease including thyroid eye disease. 

Dr. Gianoukakis directs the Thyroid Clinic and Thyroid Oncology Clinic at Harbor-UCLA where he also serves as Fellowship Training Program Director. Dr. Gianoukakis has extensive experience in clinical trials for advanced thyroid cancer. He is a member of the International Thyroid Oncology Group (ITOG) and the Southern California Thyroid Cancer Consortium (SCThyCC) as well as a medical advisor to The Thyroid Cancer Survivors’ Association (ThyCa) and The Graves’ Disease and Thyroid Foundation (GDATF).

Dr. Gianoukakis received his medical degree from University of Patras School of Medicine, Patras, Greece followed by residency in internal medicine and fellowship in endocrinology and metabolism from Albany Medical College, Albany, New York.

Andrew G. Gianoukakis is specialized in endocrinology, diabetes and metabolism with special focus on diseases like thyroid diseases, thyroid cancer, thyroid nodules, autoimmune thyroid disease, Graves’ disease, ophthalmopathy, hyperthyroidism and hypothyroidism.


Representative Publications:

Prolonged Duration of Response in Lenvatinib Responders With Thyroid Cancer

Lenvatinib Versus Placebo in Radioiodine-Refractory Thyroid Cancer

Incidence and Timing of Common Adverse Events in Lenvatinib-Treated Patients From the SELECT Trial and Their Association With Survival Outcomes

Treatment Patterns, Health State, and Health Care Resource Utilization of Patients With Radioactive Iodine Refractory Differentiated Thyroid Cancer